Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab plus pembrolizumab versus pembrolizumab in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma
2023-510323-30-00Phase 3Authorised
- Sponsor
- Genmab
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Petosemtamab plus pembrolizumab with Pembrolizumab (2 arms). Primary endpoints: Objective response rate and Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
petosemtamabpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-510323-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510323-30-00.